FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169338340> ?p ?o ?g. }

• W2169338340 endingPage "1910" @default.
• W2169338340 startingPage "1904" @default.
• W2169338340 abstract "PURPOSE Everolimus, an oral inhibitor of the mammalian target of rapamycin, has shown antitumor activity in gastric cancer in preclinical and phase I studies. This phase II study evaluated the efficacy and safety of everolimus in pretreated patients with advanced gastric cancer. PATIENTS AND METHODS Patients with advanced gastric cancer who experienced progression despite prior chemotherapy received everolimus 10 mg orally daily until disease progression or study discontinuation. The primary end point was disease control rate (DCR; ie, complete response, partial response, or stable disease). Secondary end points included progression-free survival (PFS), overall survival (OS), and safety. RESULTS Fifty-three patients were assessable (median age, 63 years; 51% and 49% received one or two prior chemotherapy regimens, respectively). Although no complete or partial response was obtained, a decrease in tumor size from baseline was observed in 45% of patients by central review. The DCR was 56.0% (95% CI, 41.3% to 70.0%); median PFS was 2.7 months (95% CI, 1.6 to 3.0 months). At a median follow-up time of 9.6 months, median OS was 10.1 months (95% CI, 6.5 to 12.1 months). Common grade 3 or 4 adverse events included anemia, hyponatremia, increased gamma-glutamyltransferase, and lymphopenia. Grade 1 or 2 pneumonitis was reported in eight patients (15.1%). CONCLUSION Everolimus monotherapy resulted in a promising DCR in patients with previously treated advanced gastric cancer. Adverse events are consistent with the reported safety profile of everolimus. These results warrant further evaluation in patients with advanced gastric cancer." @default.
• W2169338340 created "2016-06-24" @default.
• W2169338340 creator A5001115937 @default.
• W2169338340 creator A5001908825 @default.
• W2169338340 creator A5008725648 @default.
• W2169338340 creator A5010090426 @default.
• W2169338340 creator A5024904484 @default.
• W2169338340 creator A5040167138 @default.
• W2169338340 creator A5041844936 @default.
• W2169338340 creator A5053206715 @default.
• W2169338340 creator A5073330859 @default.
• W2169338340 creator A5079864042 @default.
• W2169338340 creator A5087861858 @default.
• W2169338340 creator A5089442498 @default.
• W2169338340 date "2010-04-10" @default.
• W2169338340 modified "2023-10-16" @default.
• W2169338340 title "Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer" @default.
• W2169338340 cites W1843791750 @default.
• W2169338340 cites W1965700705 @default.
• W2169338340 cites W1969624260 @default.
• W2169338340 cites W1993262126 @default.
• W2169338340 cites W1996102081 @default.
• W2169338340 cites W2017018900 @default.
• W2169338340 cites W2020830322 @default.
• W2169338340 cites W2029409133 @default.
• W2169338340 cites W2066317700 @default.
• W2169338340 cites W2068225833 @default.
• W2169338340 cites W2083240168 @default.
• W2169338340 cites W2103245073 @default.
• W2169338340 cites W2104264282 @default.
• W2169338340 cites W2104709039 @default.
• W2169338340 cites W2108661938 @default.
• W2169338340 cites W2111326166 @default.
• W2169338340 cites W2118677643 @default.
• W2169338340 cites W2122866527 @default.
• W2169338340 cites W2122995651 @default.
• W2169338340 cites W2127773543 @default.
• W2169338340 cites W2128328462 @default.
• W2169338340 cites W2131597845 @default.
• W2169338340 cites W2142398199 @default.
• W2169338340 cites W2143393758 @default.
• W2169338340 cites W2143863553 @default.
• W2169338340 cites W2144515630 @default.
• W2169338340 cites W2146473440 @default.
• W2169338340 cites W2153061032 @default.
• W2169338340 cites W2164411042 @default.
• W2169338340 cites W2169094377 @default.
• W2169338340 cites W2171075804 @default.
• W2169338340 doi "https://doi.org/10.1200/jco.2009.26.2923" @default.
• W2169338340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20231677" @default.
• W2169338340 hasPublicationYear "2010" @default.
• W2169338340 type Work @default.
• W2169338340 sameAs 2169338340 @default.
• W2169338340 citedByCount "191" @default.
• W2169338340 countsByYear W21693383402012 @default.
• W2169338340 countsByYear W21693383402013 @default.
• W2169338340 countsByYear W21693383402014 @default.
• W2169338340 countsByYear W21693383402015 @default.
• W2169338340 countsByYear W21693383402016 @default.
• W2169338340 countsByYear W21693383402017 @default.
• W2169338340 countsByYear W21693383402018 @default.
• W2169338340 countsByYear W21693383402019 @default.
• W2169338340 countsByYear W21693383402020 @default.
• W2169338340 countsByYear W21693383402021 @default.
• W2169338340 countsByYear W21693383402022 @default.
• W2169338340 countsByYear W21693383402023 @default.
• W2169338340 crossrefType "journal-article" @default.
• W2169338340 hasAuthorship W2169338340A5001115937 @default.
• W2169338340 hasAuthorship W2169338340A5001908825 @default.
• W2169338340 hasAuthorship W2169338340A5008725648 @default.
• W2169338340 hasAuthorship W2169338340A5010090426 @default.
• W2169338340 hasAuthorship W2169338340A5024904484 @default.
• W2169338340 hasAuthorship W2169338340A5040167138 @default.
• W2169338340 hasAuthorship W2169338340A5041844936 @default.
• W2169338340 hasAuthorship W2169338340A5053206715 @default.
• W2169338340 hasAuthorship W2169338340A5073330859 @default.
• W2169338340 hasAuthorship W2169338340A5079864042 @default.
• W2169338340 hasAuthorship W2169338340A5087861858 @default.
• W2169338340 hasAuthorship W2169338340A5089442498 @default.
• W2169338340 hasConcept C121608353 @default.
• W2169338340 hasConcept C126322002 @default.
• W2169338340 hasConcept C141071460 @default.
• W2169338340 hasConcept C143998085 @default.
• W2169338340 hasConcept C197934379 @default.
• W2169338340 hasConcept C203092338 @default.
• W2169338340 hasConcept C2776694085 @default.
• W2169338340 hasConcept C2777714996 @default.
• W2169338340 hasConcept C2778496288 @default.
• W2169338340 hasConcept C2778715236 @default.
• W2169338340 hasConcept C2778822529 @default.
• W2169338340 hasConcept C2779524853 @default.
• W2169338340 hasConcept C2779699572 @default.
• W2169338340 hasConcept C2779984678 @default.
• W2169338340 hasConcept C31760486 @default.
• W2169338340 hasConcept C535046627 @default.
• W2169338340 hasConcept C71924100 @default.
• W2169338340 hasConcept C90924648 @default.
• W2169338340 hasConceptScore W2169338340C121608353 @default.

• next